<DOC>
<DOCNO>
EP-0007619
</DOCNO>
<TEXT>
<DATE>
19800206
</DATE>
<IPC-CLASSIFICATIONS>
<main>A61K-9/14</main> C08L-5/00 A61K-9/08 A61K-47/42 A61K-31/715 
</IPC-CLASSIFICATIONS>
<TITLE>
galactomannan polysaccharide gum formulation containing gellation inhibitor.
</TITLE>
<APPLICANT>
wellcome foundgb<sep>the wellcome foundation limited<sep>the wellcome foundation limitedunicorn house 160 euston road p.o. box 129london nw1 2bpgb<sep>the wellcome foundation limited<sep>
</APPLICANT>
<INVENTOR>
gayst stephen<sep>maguire michael john<sep>gayst, stephen<sep>maguire, michael john<sep>gayst, stephen19 arthur streetdouble bay new south wales 2028au<sep>maguire, michael john9 cotton streetepping new south wales 2121au<sep>gayst, stephen  <sep>maguire, michael john <sep>gayst, stephen19 arthur streetdouble bay new south wales 2028au<sep>maguire, michael john9 cotton streetepping new south wales 2121au<sep>
</INVENTOR>
<ABSTRACT>
the gellation of polysaccharide gums such as guar or  locust bean gum is inhibited by gelatin hydrolysates, at  alkaline ph.  formulations of gum, gelatin hydrolysate and  alkaliniser are reconstituted by shaking with water, and are  easily imbibed.  the inhibition is reversed by ph change in the  stomach allowing gellation to occur, the formulation is useful  in treatment of hypercholesteraemia, gastric disorders and as  an adjunct to insulin therapy.  
</ABSTRACT>
</TEXT>
</DOC>
